Free Trial

Bavarian Nordic (OTCMKTS:BVNRY) Sees Strong Trading Volume - Here's What Happened

Bavarian Nordic logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Trading surge: Bavarian Nordic saw intraday volume of 7,167 shares, a 377% increase from the prior session's 1,503 shares, with the stock trading around $9.58 (previous close $9.5840).
  • Valuation and technicals: The stock sits below its 50‑day ($10.17) and 200‑day ($10.80) moving averages and has a market capitalization of $2.28 billion, a P/E of 6.18 and a beta of 1.34.
  • Business profile: Bavarian Nordic is a fully integrated biotech focused on vaccines and immunotherapies, commercializing products including Jynneos (Imvamune/Imvanex), Rabipur and Encepur.
  • MarketBeat previews the top five stocks to own by May 1st.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) saw strong trading volume on Tuesday . 7,167 shares changed hands during mid-day trading, an increase of 377% from the previous session's volume of 1,503 shares.The stock last traded at $9.58 and had previously closed at $9.5840.

Bavarian Nordic Price Performance

The company has a 50-day moving average of $10.17 and a two-hundred day moving average of $10.80. The company has a market capitalization of $2.28 billion, a PE ratio of 6.18 and a beta of 1.34.

About Bavarian Nordic

(Get Free Report)

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic's operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company's commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bavarian Nordic Right Now?

Before you consider Bavarian Nordic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bavarian Nordic wasn't on the list.

While Bavarian Nordic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines